Holen Sie sich die Stockscreener-App
44.83
1.77%
0.77
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
(MIRM) Proactive Strategies - Stock Traders Daily
Mirum Pharmaceuticals Strengthens Growth Strategy with Strategic New Hires and Equity Incentives - StockTitan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Mirum Pharmaceuticals director Heron buys $83,661 in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals director Heron buys $83,661 in stock - Investing.com India
Director’s Bold Move: Major Stock Purchase in Mirum Pharmaceuticals! - TipRanks
Mirum Pharmaceuticals’ president sells $676,928 in stock - Investing.com India
Mirum Pharmaceuticals’ president sells $676,928 in stock By Investing.com - Investing.com UK
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Rhumbline Advisers - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $72.00 - Defense World
Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know - MSN
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $72.00 at HC Wainwright - MarketBeat
Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report - Yahoo Finance
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates - MSN
(MIRM) Technical Data - Stock Traders Daily
Mirum Pharmaceuticals: Strong Buy Rating Driven by Promising Financial Growth and Clinical Advancements - TipRanks
Mirum Pharmaceuticals (NASDAQ:MIRM) Trading Down 8.2% After Earnings Miss - MarketBeat
Robert W. Baird Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price - MarketBeat
H.C. Wainwright lifts Mirum stock target to $72, maintains Buy By Investing.com - Investing.com UK
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2024 Earnings Call Transcript - Insider Monkey
Mirum Pharmaceuticals’ Earnings Call Highlights Growth and Future Prospects - TipRanks
Mirum Pharmaceuticals (NASDAQ:MIRM) Announces Quarterly Earnings Results - MarketBeat
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates - MSN
Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ... By GuruFocus - Investing.com Canada
Phocas Financial Corp. Sells 32,190 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals misses Q4 earnings, stock falls - Investing.com India
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Mirum Pharmaceuticals Reports Strong 2024 Growth - TipRanks
Mirum Pharmaceuticals: Strong Financial Performance and Strategic Advancements Drive Buy Rating - TipRanks
Mirum Pharmaceuticals earnings missed by $1.55, revenue topped estimates - Investing.com South Africa
Mirum Pharmaceuticals misses Q4 earnings, stock falls By Investing.com - Investing.com South Africa
Earnings call transcript: Mirum Pharmaceuticals misses Q4 2024 EPS forecast - Investing.com
Mirum Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Earnings Flash (MIRM) Mirum Pharmaceuticals Reports Q4 Revenue $99.4M, vs. FactSet Est of $96.6M - Marketscreener.com
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update - Business Wire
Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts - Yahoo Finance
Mirum Pharmaceuticals' SWOT analysis: FDA approvals boost rare disease stock - Investing.com
Mirum drug for rare genetic disease gains FDA approval - BioPharma Dive
Deal pays off for drugmaker with approval for rare cholesterol-related disease treatment - The Business Journals
Mirum Pharmaceuticals Says US FDA Approves Cerebrotendinous Xanthomatosis' Treatment Drug - Marketscreener.com
Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX) - The Bakersfield Californian
Medical Milestone: First Treatment for CTX Patients Shows 20x Better Results Than Placebo - StockTitan
JMP maintains $74 target on Mirum Pharmaceuticals stock By Investing.com - Investing.com South Africa
JMP maintains $74 target on Mirum Pharmaceuticals stock - Investing.com India
FDA approves Mirum’s Ctexli for cerebrotendinous xanthomatosis - Yahoo Finance
US FDA approves Mirum Pharma's genetic disorder drug - MSN
Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 12-Month HighHere's What Happened - MarketBeat
Mirum Pharmaceuticals (MIRM) Expected to Announce Earnings on Wednesday - MarketBeat
Mirum’s Ctexli wins FDA nod in cerebrotendinous xanthomatosis - BioWorld Online
Mirum Pharmaceuticals' Lipid Storage Disease Treatment Gets FDA Approval -February 21, 2025 at 01:48 pm EST - Marketscreener.com
US FDA approves Mirum Pharma’s genetic disorder drug - KFGO
2.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):